N-[2-(Benzoylamino)-6-benzothiazolyl]tricyclo[3.3.1.13,7]decane-1-carboxamide

NVP-231 (362003-83-6) is a reversible inhibitor of ceramide kinase (IC50 = 12 nM).1 At 10 nM, it inhibited ceramide-1-phosphate formation by >50% and at 100 nM it completely inhibited its formation in cell culture.? NVP-231 was inactive against hSphK1/2, hPI3Ka, hPI4Kb, hVps34, hGCS, hSMS-1, CERT, and 500-fold less potent against hDAGKa.? NVP-231 inhibited breast and lung cancer cell proliferation via M phase arrest.2 It potently blocked cell migration and invasion in PANC-1 pancreatic cancer cells3 as well as MDA-MB-231 breast cancer cells4.

A ceramide kinase inhibitors that completely inhibits binding of ceramide to CerK and protects against C2-Cer-induced cell death.

Store at +4°C

Graf et al. (2008), Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor; Mol. Pharmacol., 74 925 Pastukhov et al. (2014), The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death; Br. J. Pharmacol., 171 5829 Rivera et al. (2016), Ceramide-1-phosphate regulates cell migration and invasion of human pancreatic cancer cells; Biochem. Pharmacol., 102 107 Schwalm et al. (2020), Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI3-Kinase and Akt; Int. J. Mol. Sci., 21 1396